Beta Drugs Limited has achieved significant regulatory milestones in Azerbaijan and the Philippines, marking important progress in the company's international expansion strategy. These developments strengthen the company's access to CIS and Southeast Asian markets while enhancing export sales opportunities.

Azerbaijan GMP Inspection Success

The company's manufacturing facility underwent a successful inspection by the Ministry of Health of Azerbaijan Republic from April 13, 2026 to April 17, 2026. Beta Drugs expects to receive Good Manufacturing Practice (GMP) approval within the next one to two months following this inspection.

This approval, combined with the company's existing Eurasian Economic Union (EAEU) approval, is expected to enable market entry in Azerbaijan and strengthen commercialization opportunities across the broader CIS region.

Philippines Product Registration Achievement

Beta Drugs has received Certificates of Product Registration (CPR) for two brands in the Philippines market. Both products represent the first generic approvals in their respective categories, providing the company with an opportunity to establish early market presence.

The company anticipates receiving further approvals over the next six months, which are expected to expand its presence in the Philippines and provide a foundation for planned entry into other Southeast Asian markets, including Vietnam and Thailand.

Strengthening International Regulatory Portfolio

These regulatory developments build upon Beta Drugs' existing approvals from PIC/S, ANVISA, INVIMA, and the Eurasian Economic Union (EAEU). The company has also initiated the process for European Union Good Manufacturing Practice (EU GMP) inspection.

These achievements reinforce the company's presence in regulated international markets and are expected to strengthen international filings while supporting future export revenues. The systematic approach to regulatory compliance demonstrates Beta Drugs' commitment to meeting international pharmaceutical standards across multiple jurisdictions.

Beta Drugs Ltd shares surged over 4% following the company's announcement of acquiring a controlling stake in IVF specialist Nivian Lifesciences. The oncology drug manufacturer's stock reached a day's high of ₹1,653.10 per share, up from the previous day's closing price of ₹1,585.00 per share, with the company's market capitalization standing at ₹1,565.00 crore.

Strategic Acquisition Details

Beta Drugs has signed a definitive agreement to acquire a 66.09% controlling stake in Nivian Lifesciences Pvt. Ltd from existing shareholders. The acquisition parameters are outlined below:

This acquisition marks Beta Drugs' first entry into the women's health and fertility drug segment, representing a strategic diversification from its core oncology business.

About Nivian Lifesciences

Nivian Lifesciences, established in 2019 by Nilesh Auti, specializes in branded formulations for IVF therapy medicines in India. Despite being relatively new, the company has established a strong position in the IVF pharmaceutical space with impressive growth metrics.

As part of the agreement, founder Nilesh Auti will continue overseeing marketing and operations while retaining his stake to support the company's next growth phase.

Beta Drugs H1 FY26 Financial Performance

Beta Drugs reported mixed financial results for H1 FY26, with strong revenue growth but marginal profit decline:

Business Segment Performance

The company's domestic business showed robust growth, increasing its contribution to overall revenue:

International Market Distribution

Beta Drugs' international operations span across multiple regions:

• APAC Region: 48% of international sales
• Latin America: 25% of international sales
• Africa: 23% of international sales
• MENA Region: 4% of international sales

Company Background and Market Position

Beta Drugs Ltd operates as one of India's leading manufacturers of oncology drugs, specializing in complex chemical synthesis for both anti-cancer bulk drugs and finished formulations. Under the leadership of Managing Director Rahul Batra and Joint Managing Director Varun Batra, the company supplies products to over 50 major pharmaceutical companies throughout India and exports to more than 46 countries.

The stock has delivered exceptional long-term returns of 1,215% over the past five years, significantly outperforming the NIFTY 50's return of 77% during the same period. Notable investor Ashish Kacholia holds a 5.78% stake in the company as of Q2 FY26, having gradually increased his position from 5.72% in March 2023.